Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
Type:
Grant
Filed:
August 31, 2016
Date of Patent:
August 7, 2018
Assignee:
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Abstract: The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.
Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Type:
Grant
Filed:
October 15, 2012
Date of Patent:
July 24, 2018
Assignee:
CELATOR PHARMACEUTICALS, INC.
Inventors:
Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
Type:
Grant
Filed:
March 5, 2013
Date of Patent:
July 24, 2018
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Lois Gibson, William Joseph Lambert, Benjamin W. Li, Liangjin Zhu
Abstract: The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.
Abstract: Liposomal compositions comprising peptide epoxyketone compounds are described, as well as methods of making and using such liposomal compositions. These liposomal compositions enhance the therapeutic window of peptide epoxyketone compounds by improving in vivo half-life relative to non-liposomal compositions comprising peptide epoxyketone compounds, providing desirable pharmacodynamic profiles, and providing anti-tumor activity in a human tumor xenograft model, greater than or equal to non-liposomal compositions comprising peptide epoxyketone compounds. Further, experiments performed in support of the present invention demonstrated improved tolerability of liposomal compositions comprising peptide epoxyketone compounds.
Type:
Grant
Filed:
July 17, 2013
Date of Patent:
July 17, 2018
Assignee:
Onyx Therapeutics, Inc.
Inventors:
Katherine A. Chu, Elena T. Chan, Ying Fang, Mouhannad Jamaa, Christopher Justin Kirk, Tony Muchamuel, Zhengping Wang, Jing Jiang, Jeffrey Joseph Jones
Abstract: A liposome of irinotecan or irinotecan hydrochloride and its preparation method are disclosed. The liposome contains irinotecan or irinotecan hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of the cholesterol to the neutral phospholipid is 1:3 to 1:5. The liposome is prepared by an ion gradient method.
Abstract: A method of preparing liposomes, liposome compositions formed by the process, and methods of using the liposome composition are provided herein.
Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.
Abstract: Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.
Type:
Grant
Filed:
March 12, 2015
Date of Patent:
June 19, 2018
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Patrick J. Sinko, Stanley Stein, Anita Lalloo
Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.
Abstract: Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Abstract: It is intended to provide a liposome preparation which is a liposome, has a lipid bilayer membrane composed of an inner membrane constituted by a lipid including one or more types of functional lipids (a lipid capable of chemically interacting with another compound such as a charged lipid, a polarizable lipid, a lipid-soluble lipid or a water-soluble lipid) and an outer membrane constituted by a lipid with or without including one or more types of functional lipids, and is characterized in that at least a condition that the amount of any one type of functional lipid contained in the inner membrane is larger than in the outer membrane is satisfied. The liposome preparation is suitable as a liposome for encapsulating a contrast agent (a neutral substance having a hydroxy group), siRNA (an anionic substance) having an anticancer activity or the like. Its encapsulation ratio of drug agents, dispersion stability, control release and the like have been improved.
Abstract: The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C.
Type:
Grant
Filed:
June 17, 2010
Date of Patent:
May 29, 2018
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Hansj{hacek over (o)}rg Eibl, Lars H. Lindner
Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
May 22, 2018
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
Abstract: The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents.
Abstract: Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Abstract: The present invention provides a method of manufacture of a liposome composition including a step in which: a liposome dispersion liquid containing a liposome, and further containing cyclodextrin in the liposome internal phase is provided and a step in which an active compound is introduced into said liposome internal phase, and the liposome composition.
Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
May 1, 2018
Assignees:
Nanyang Technological University, Singapore Health Services Pte Ltd
Inventors:
Subramanian Venkatraman, Jayaganesh V. Natarajan, Tina Howden, Freddy Boey
Abstract: The invention concerns a method for extemporaneous and reversible concentration of liposomes, the mixed liposome-cyclodextrin aggregates obtainable by the method, and uses thereof in the pharmaceutical, diagnostic and cosmetic field.
Type:
Grant
Filed:
April 30, 2007
Date of Patent:
February 20, 2018
Assignee:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)